inhibitor, for the symptomatic treatment of mild or moderate dementia in Alzheimer's disease has been strongly welcomed by patients, relatives and professionals, bringing optimism on a previously desolate scene. However, the introduction of this completely novel treatment1'2 has generated clinical, moral, ethical and economic dilemmas3. Here we highlight some issues that require further attention.
CONSENT TO TREATMENT
The Royal College of Psychiatrists has expressed the view that, in general, treatment with an anti-dementia drug requires the patient's consent4.
However, many patients with dementia will be incapable of providing informed consent. Should they be denied treatment by strict interpretation of these guidelines? In our view, the advent of new drugs does not alter the principles of management whereby professionals act in these individuals' best interest, often with the relatives' agreement and assent under common law. For example, inability to give informed consent would not be a reason for denying antibiotics-or, indeed, placement in nursing homes. In the UK, the Mental Health Act offers no way out because it requires admission to hospital. This would not be so in the Australian state of Victoria and other societies that can apply community treatment orders. As things are in the UK, the requirement of informed consent might offer some health authorities a mechanism for rationing of expensive drugs of this sort.
IS THE TREATMENT WORKING?
Clinical trials have shown that treatment groups fare better than placebo groupsl ,2. However, the action is probably to slow cognitive decline rather than alter the disease process.
Thus, efficacy in an individual patient is difficult to evaluate-even if we concentrate on cognition rather than the functional indices that mean more to patients and carers. Drug holidays have been suggested in cases where the efficacy is doubtful4'5; a rapid decline in cognition after withdrawal of the drug might then provide evidence of efficacy. In trials of donezepil, patients on active treatment deteriorated rapidly during such washout periods. In the shorter of the two main studies1, the benefit from 3mg donezepil, significant at the 12-week endpoint, had disappeared after 2 weeks of washout; in those receiving 5mg donezepil some benefit was still apparent after 2 weeks' washout, though the size of the effect was reduced. In the longer study2, the benefits from both 5 mg and 10 mg donezepil were lost after 6 weeks' washout. We must, however, consider the possibility that rapid deterioration on discontinuation was a withdrawal effect akin to that seen with benzodiazepines.
STARTING AND STOPPING TREATMENT
The prevailing view is that donezepil does not affect the process of Alzheimer's disease. Patients and carers, of course, are looking for a cure; and the message that treatment will at best slow the rate of deterioration needs to be transmitted sensitively. The medical community seems to have been 'caught on the hop' with regard to the licensing and emergence of donezepil. For example, the Royal College of Psychiatrists' guidelines on prescription of new anti-dementia drugs emerged two months after the licensing of donepezil. Several months later, many health authorities remain uncertain whether the drug should be made available. Meanwhile the drug is being promoted, and the strategies for its advertising in medical journals have come under criticism6'7. There is a parallel with ,Binterferon for multiple sclerosis another expensive drug with marginal benefits, approved by some health authorities but not all. Inequity is a consequence.
Once treatment is started, is there a point at which it ceases to act? At some time we might expect the unchecked process of cell loss in neurotransmitter systems to defeat all pharmacological endeavours; but there are so far no clinical data to help us in individual cases. At present, pressure from relatives will probably result in long-term, perhaps indefinite, prescription, irrespective of efficacy.
Clinical studies have focused largely on measures of cognitive function. Dementia is a multifaceted illness with some components (for example, behaviour disturbance) having greater impact on the functional ability of the patient and the perceived burden of care. The effect of donezepil Department of Psychiatry of Old Age, Charing Cross and Westminster Medical School, London, UK Correspondence to: Dr Ajit Shah, West Middlesex University Hospital, lsleworth TW7 6AF, UK on affective features, psychotic features, behavioural disturbance, personality change, functional disability and carer stress is unclear. Depression and dementia may coexist in some patients and others may have a depressive pseudodementia. In the past, such patients would have received a trial of an antidepressant. However, in the absence of data on the effect of donezepil on affective features, it will be difficult to decide whether antidepressants or donezepil should be used first. If antidepressants are used first and prove ineffective, then treatment with donezepil will have been delayed.
MONITORING AND SUPERVISION
Monitoring of change will also pose difficulties. The evidence-based approach implies that the patients receiving anti-dementia drugs8, and the techniques of monitoring, should closely resemble those used in the clinical trials. But the trialists employed time-consuming and cumbersome techniques that would be quite impractical in ordinary circumstances. There is no consensus on the general criteria for monitoring change, and without such criteria different units are likely to develop different systems for monitoring. This, of course, has resource implications. Another implication for resources, already apparent, is that patients previously not referred to secondary services will now be referred as possible candidates for donepezil, thus increasing the clinical workload. Finally, for patients in whom the drug is prescribed, there is the matter of compliance. Patients with dementia living alone at home may well forget to take their pills. Should these patients receive daily district nurse or community psychiatric nurse visits? Such services would add greatly to the costs of the drug itself.
COSTS AND BENEFITS
In the UK, the cost of dementia to society approaches £1.1 billion a year9'10, social service costs being a major contributor9. If donepezil delays admission to residential or nursing homes, prescription of this drug could reduce social service costs while increasing those to health services; this has been demonstrated with the anti-dementia drug tacrine1l ,12. Ideally the savings on social services would be diverted to the health sector; but this is not the way things work in the UK, where health and social service budgets unite only at the Treasury. We badly need national studies of the pharmacoeconomics of treatment with donezepil-at the levels of the individual, family, health service and society. In some countries, donezepil would not have been licensed in the existing state of ignorance.
